Clinical Trial Update: A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the safety of continuing enzalutamide (MDV3100) in men with castration-resistant prostate cancer who previously benefited from M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Castration-Resistant Prostate Cancer (CRPC) | Phase 2 | Status: COMPLETED | Results posted: 2018-04-27